GB0402679D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0402679D0
GB0402679D0 GBGB0402679.5A GB0402679A GB0402679D0 GB 0402679 D0 GB0402679 D0 GB 0402679D0 GB 0402679 A GB0402679 A GB 0402679A GB 0402679 D0 GB0402679 D0 GB 0402679D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
arylcarbonylamino
ibs
pent
cough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0402679.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0402679.5A priority Critical patent/GB0402679D0/en
Publication of GB0402679D0 publication Critical patent/GB0402679D0/en
Priority to EP05707213A priority patent/EP1715848B1/en
Priority to PT05707213T priority patent/PT1715848E/pt
Priority to RU2006131788/15A priority patent/RU2397759C2/ru
Priority to BRPI0507492-4A priority patent/BRPI0507492A/pt
Priority to DE602005022558T priority patent/DE602005022558D1/de
Priority to ES05707213T priority patent/ES2349647T3/es
Priority to CN2005800081031A priority patent/CN1929817B/zh
Priority to US10/597,313 priority patent/US20080254113A1/en
Priority to CA002553658A priority patent/CA2553658A1/en
Priority to PL05707213T priority patent/PL1715848T3/pl
Priority to AT05707213T priority patent/ATE475409T1/de
Priority to JP2006551813A priority patent/JP2007520521A/ja
Priority to PCT/EP2005/001166 priority patent/WO2005074891A1/en
Priority to AU2005210134A priority patent/AU2005210134B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0402679.5A 2004-02-06 2004-02-06 Organic compounds Ceased GB0402679D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0402679.5A GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds
AU2005210134A AU2005210134B2 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance P antagonists
ES05707213T ES2349647T3 (es) 2004-02-06 2005-02-04 Formulaciones de microemulsión que comprenden antagonistas de sustancia p particulares.
US10/597,313 US20080254113A1 (en) 2004-02-06 2005-02-04 Microemulsion Formulations Comprising Particular Substance P Antagonists
RU2006131788/15A RU2397759C2 (ru) 2004-02-06 2005-02-04 Микроэмульсионные композиции, включающие антагонисты вещества р
BRPI0507492-4A BRPI0507492A (pt) 2004-02-06 2005-02-04 formulações de microemulsão compreendendo antagonistas de substáncia p
DE602005022558T DE602005022558D1 (de) 2004-02-06 2005-02-04 Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten
EP05707213A EP1715848B1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists
CN2005800081031A CN1929817B (zh) 2004-02-06 2005-02-04 包含特定的p物质拮抗剂的微乳制剂
PT05707213T PT1715848E (pt) 2004-02-06 2005-02-04 Formulações em microemulsão compreendendo certos antagonistas da substância p
CA002553658A CA2553658A1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists
PL05707213T PL1715848T3 (pl) 2004-02-06 2005-02-04 Preparaty mikroemulsyjne zawierające szczególnych antagonistów substancji P
AT05707213T ATE475409T1 (de) 2004-02-06 2005-02-04 Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten
JP2006551813A JP2007520521A (ja) 2004-02-06 2005-02-04 特定のサブスタンスｐアンタゴニストを含んでなるマイクロエマルジョン製剤
PCT/EP2005/001166 WO2005074891A1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402679.5A GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds

Publications (1)

Publication Number Publication Date
GB0402679D0 true GB0402679D0 (en) 2004-03-10

Family

ID=31985813

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0402679.5A Ceased GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds

Country Status (15)

Country Link
US (1) US20080254113A1 (https=)
EP (1) EP1715848B1 (https=)
JP (1) JP2007520521A (https=)
CN (1) CN1929817B (https=)
AT (1) ATE475409T1 (https=)
AU (1) AU2005210134B2 (https=)
BR (1) BRPI0507492A (https=)
CA (1) CA2553658A1 (https=)
DE (1) DE602005022558D1 (https=)
ES (1) ES2349647T3 (https=)
GB (1) GB0402679D0 (https=)
PL (1) PL1715848T3 (https=)
PT (1) PT1715848E (https=)
RU (1) RU2397759C2 (https=)
WO (1) WO2005074891A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
RU2481822C1 (ru) * 2012-02-21 2013-05-20 Автономная некоммерческая организация "Институт медико-биологических исследований и технологий" (АНО "ИМБИИТ") Микроэмульсионные композиции для создания трансдермальных и трансмукозальных форм фармацевтических средств и косметических препаратов и способ их получения
AU2014204739B2 (en) * 2013-01-14 2016-08-11 Infirst Healthcare Limited Compositions and methods for treating severe pain
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
NZ502567A (en) * 1997-07-29 2002-03-28 Upjohn Co Self-emulsifying formulation for lipophilic compounds containing a pyranone and a mixture of monoglycerides and diglycerides
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
MY120392A (en) * 2000-06-08 2005-10-31 Hovid Berhad A novel drug delivery system : formulation for fat-soluble drugs

Also Published As

Publication number Publication date
DE602005022558D1 (de) 2010-09-09
BRPI0507492A (pt) 2007-07-17
PL1715848T3 (pl) 2011-01-31
CN1929817B (zh) 2012-04-25
EP1715848A1 (en) 2006-11-02
ATE475409T1 (de) 2010-08-15
CN1929817A (zh) 2007-03-14
RU2397759C2 (ru) 2010-08-27
EP1715848B1 (en) 2010-07-28
AU2005210134A1 (en) 2005-08-18
CA2553658A1 (en) 2005-08-18
WO2005074891A1 (en) 2005-08-18
US20080254113A1 (en) 2008-10-16
ES2349647T3 (es) 2011-01-07
AU2005210134B2 (en) 2008-05-22
PT1715848E (pt) 2010-10-21
RU2006131788A (ru) 2008-03-20
JP2007520521A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
MX2009004289A (es) Compuestos triciclicos como inhibidores de metaloproteinasas matriciales.
BR0107934A (pt) Carboxamidas de pirimidina úteis como inibidores de isozimas pde4
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
ZA200806778B (en) N-Hydroxyacrylamide compounds
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
MY145919A (en) Pharmaceutical formulation comprising neurokinin antagonist
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
HRP20140707T1 (hr) KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
EP1737499A4 (en) TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
TW200720236A (en) Organic compounds
EA200601880A1 (ru) Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
MX2007001444A (es) Glicosidos sulfatados y sales de los mismos.
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
GB0402679D0 (en) Organic compounds
EA200701879A1 (ru) Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина
MX2010004529A (es) Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
MX2010012019A (es) Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)